RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea- 
Introduction
Polycythemia vera (PV) is a myeloproliferative neoplasm primarily characterized by erythrocytosis, although increased white blood cell and platelet counts are also common. 1 Patients with PV have increased risks of morbidity and mortality relative to comparable subjects in the general population (eg, same sex/age), 2, 3 often resulting from thromboembolic events or progression to myelofibrosis (MF) or acute myeloid leukemia (AML). 2 Treatment for PV aims to reduce the risk of thromboembolic events, relieve symptom burden, and minimize the risk of disease transformation to MF or AML. 4, 5 Some patients obtain clinical benefit from cytoreductive treatment, often hydroxyurea [6] [7] [8] ; however, approximately 25% of patients become resistant to or intolerant of hydroxyurea. 9 Ruxolitinib is a Janus kinase (JAK)1/JAK2 inhibitor approved by the US Food and Drug Administration (FDA) for patients with PV who have an inadequate response to or are intolerant of hydroxyurea 10 and by the European Medicines Agency (EMA) for adult patients with PV who are resistant to or intolerant of hydroxyurea.
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The ongoing RESPONSE trial is a global, multicenter, phase 3 study comparing ruxolitinib with best available therapy in patients with PV who were resistant to or intolerant of hydroxyurea, per modified European LeukemiaNet (ELN) criteria. 4, 12 In the primary analysis, a significantly greater proportion of patients treated with ruxolitinib achieved hematocrit control without phlebotomy along with a ≥ 35% reduction in spleen volume from Baseline at Week 32 (the primary study endpoint) compared with patients treated with best available therapy. 12 This was a second preplanned analysis of the RESPONSE trial assessing durability of efficacy and the long-term safety of ruxolitinib treatment after all patients completed the Week 80 visit or discontinued the study.
Methods

Study Design
RESPONSE is an international, randomized, open-label, phase 3 study (ClinicalTrials.gov identifier, NCT01243944). The study design and primary analysis results have been described previously. 12 Briefly, eligible patients were randomized 1:1 to receive ruxolitinib (10 mg twice daily) or best available therapy (single-agent therapy deemed most appropriate by treating physician). Treatment options for best available therapy included hydroxyurea, interferon or pegylated interferon, pipobroman, anagrelide, immunomodulators (eg, lenalidomide, thalidomide), or observation without pharmacologic treatment (except aspirin). Dose adjustments were permitted for safety and efficacy in patients receiving ruxolitinib; modifications could be made to best available therapy regimens for lack of response or side effects requiring treatment discontinuation. Low-dose aspirin was administered to all patients unless contraindicated. Phlebotomies as monotherapy or in combination with study treatment were mandatory for patients with a confirmed hematocrit >45% that was ≥ 3 percentage points higher than Baseline or a confirmed hematocrit >48%, whichever was lower.
Patients randomized to best available therapy were permitted to cross over to ruxolitinib Please see the supplemental section for details concerning exploratory and statistical analyses included in this report.
Results
Patients
In total, 222 patients were randomized to ruxolitinib (n=110) or best available therapy (n=112); patient enrollment and demographics were previously reported. 12 Table S1 ). After 32 weeks of treatment, the mean percentage change from original Baseline in spleen volume was -27.7% in patients originally randomized to ruxolitinib and -14.2% in those receiving ruxolitinib after crossover, and +4.5% in those receiving best available therapy.
The positive trend toward improved (ie, reduced) blood cell counts observed in patients originally randomized to ruxolitinib was also observed in patients treated with ruxolitinib after crossover (Figure 4) .
JAK2V617F Allele Burden
The mean (median) percentage change from Baseline in JAK2V617F allele burden at Crossover Baseline in JAK2V617F allele burden was -6.7% (-5.5%) 48 weeks after crossover.
Safety
The most common nonhematologic adverse events in the originally randomized ruxolitinib arm were headache, diarrhea, pruritus, and fatigue (Table 1) ; most events were grade 1 or 2. Relatively few new adverse events were observed after the primary analysis; the number of patients with any given adverse event from the 48-week to the 80-week analysis increased by no more than 4 and by 1 or 2 for most individual events.
New or worsening hematologic laboratory abnormalities in the originally randomized ruxolitinib arm through Week 80 were primarily grade 1 or 2 decreases in hemoglobin, lymphocytes, and platelets (Table 2) . Patients receiving treatment with ruxolitinib after crossover had a higher rate of decreased hemoglobin compared with those originally randomized to ruxolitinib; the rates of other hematologic adverse events ( with best available therapy, n=7), rates of nonmelanoma skin cancer were similar between randomized treatments (24.2, 10.6, 22.3 per 100 patient-years of exposure, respectively). Among patients without a history of nonmelanoma skin cancer (originally randomized to ruxolitinib, n=98; with ruxolitinib after crossover, n=92; with best available therapy, n=104), rates of nonmelanoma skin cancer were 2.0, 1. crossover from best available therapy achieved similar benefits in hematocrit control, reduction in spleen volume, and normalization of blood cell counts as patients originally randomized to ruxolitinib. Furthermore, although patient-reported symptom severity was not assessed after Week 32, fatigue and pruritus were recorded as adverse events throughout the study. These events continued to occur at lower rates in patients who were randomized to or crossed over to ruxolitinib compared with those receiving best available therapy.
Control of blood cell counts is an important treatment goal for patients with PV. A largescale randomized controlled trial testing the intensity of cytoreductive therapy in PV
(CYTO-PV) demonstrated that high hematocrit levels (45%-50% vs <45%) and high white blood cell counts (≥11×10 9 /L vs <7.0×10 9 /L) are associated with increased risk of cardiovascular/thromboembolic events. 6, 13 However, maintaining a therapeutic hematocrit level with phlebotomy and/or hydroxyurea may be challenging for some patients. In the CYTO-PV study, approximately 25% of patients had hematocrit levels that were outside the target range 6 months after randomization. 14 Treatment with ruxolitinib in RESPONSE was associated with durable improvements in hematocrit levels, as well as reductions in white blood cell counts. Furthermore, although the study was not designed to evaluate thromboembolic event rates, the originally randomized ruxolitinib arm of RESPONSE was associated with a lower rate of thromboembolic events compared with the best available therapy arm. At Week 32, before crossover to ruxolitinib, there were 6 thromboembolic events in the best available therapy group compared with 1 event in the ruxolitinib arm. 12 Although treatment with ruxolitinib after crossover was associated with rapid normalization of blood cell counts, thromboembolic event rates remained higher than in patients originally randomized to ruxolitinib. These analysis. The rate of herpes zoster continues to be higher in the originally randomized ruxolitinib arm, as reported in the primary analysis. 12 Most herpes zoster infections were grade 1 or 2 and were resolved without sequelae. Nonmelanoma skin cancers were observed in the originally randomized ruxolitinib arm, mainly in patients with a history of nonmelanoma skin cancer or precancer; however, exposure-adjusted rates at the time of this analysis were generally similar between the originally randomized ruxolitinib and best available therapy arms. Rates of transformation to MF and AML were consistent with published rates for similar patient populations with PV. 9, 15, 16 These safety and tolerability data are important because many patients require long-term therapy to manage their PV.
Hydroxyurea is often prescribed for patients who require cytoreductive treatment. 
